RADIOPHARMACEUTICAL AND CHEMOTHERAPY TREATMENT OF METASTATIC PHEOCHROMOCYTOMA

转移性嗜铬细胞瘤的放射药物和化疗治疗

• 批准号: 6244566
• 负责人: JAMES C SISSON
• 金额: $ 2.22万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-20 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244566
• 关键词: clinical research; combination cancer therapy; cyclophosphamide; dacarbazine; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer radionuclide therapy; neoplasm /cancer remission /regression; pheochromocytoma; vincristine

We propose a more vigorous treatment of malignant pheochromocytomas using two approaches that have shown promise: 131-I metaiodobenzylguanidine (131-I MIBG) and three-agent chemotherapy. The goal is to attain complete remissions in 30% of treated patients. Innovation is combining sequentially two different types of therapy for a cancer that has resisted previous treatments.

我们建议对恶性嗜铬细胞瘤采取更有力的治疗 使用两种已经显示出希望的方法：131-I 间碘苄胍（131-I MIBG）和三剂化疗。的 目标是在30%的治疗患者中实现完全缓解。 创新是将两种不同类型的治疗方法依次结合起来， 一种对以前的治疗有抵抗力的癌症。